Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan (Drs Tada, Usui, Sakata, and Takamura).
Department of Clinical Genetics, Ishikawa Prefectural Central Hospital, Kanazawa, Japan (Dr Nohara).
J Clin Lipidol. 2024 Sep-Oct;18(5):e825-e831. doi: 10.1016/j.jacl.2024.06.008. Epub 2024 Jul 6.
The 2022 Japan Atherosclerosis Society familial hypercholesterolemia (FH) clinical criteria were modified. In particular, the cutoff value of Achilles tendon thickness (ATT) on radiography was changed from ≥9 mm in both sexes to ≥8.0 mm in men and ≥7.5 mm in women.
A total of 872 patients with FH were retrospectively reviewed. Patients were categorized by an ATT of <7.5/8.0 mm (group 1), ≥7.5/8.0 and <9.0 mm (group 2, new group with FH by ATT), and ≥9 mm (group 3).
In total, 492 patients fell into group 1, 102 in group 2, and 263 in group 3, and 14.0%, 55.9%, and 79.8% of patients in groups 1, 2, and 3, respectively, were positive for a FH mutation. Further, among patients with low-density lipoprotein cholesterol >180 mg/dL, 37.3%, 77.3%, and 86.5% of patients had a FH mutation in groups 1, 2, and 3, respectively. The proportion of patients with protein-truncating mutation (3.8%, 16.7%, and 53.2%, respectively) differed significantly across groups 1 through 3, respectively. Interestingly, only a very small proportion of the patients in groups 2 and 3 had palpable xanthomas (3.0% and 14.4% respectively).
This study validates the new radiographic ATT criteria, since the vast majority of patients in the intermediate ATT category had true FH, as shown by positive genetic testing, whereas the old ATT criteria left them with just a deferred diagnosis of FH. In addition, use of physical examination alone for the presence of tendon xanthoma may lead to underdiagnosis of FH.
2022 年日本动脉粥样硬化学会家族性高胆固醇血症(FH)临床标准进行了修订。特别是,放射影像学上跟腱厚度(ATT)的截断值由男女均≥9mm 改为男性≥8.0mm 和女性≥7.5mm。
回顾性分析 872 例 FH 患者。根据 ATT<7.5/8.0mm(组 1)、≥7.5/8.0 且<9.0mm(组 2,新的 ATT 阳性 FH 组)和≥9.0mm(组 3)对患者进行分类。
共 492 例患者归入组 1,102 例归入组 2,263 例归入组 3。组 1、2 和 3 中分别有 14.0%、55.9%和 79.8%的患者 FH 突变阳性。进一步分析,在 LDL-C>180mg/dL 的患者中,组 1、2 和 3 中分别有 37.3%、77.3%和 86.5%的患者 FH 突变阳性。组 1 到 3 之间,发生蛋白截断突变的患者比例(分别为 3.8%、16.7%和 53.2%)差异有统计学意义。有趣的是,组 2 和 3 中只有极少数患者有可触及的黄色瘤(分别为 3.0%和 14.4%)。
本研究验证了新的放射影像学 ATT 标准,因为绝大多数中间 ATT 类别的患者均通过阳性基因检测证实存在真正的 FH,而旧的 ATT 标准则使他们只能被延迟诊断为 FH。此外,单独通过体格检查来发现肌腱黄色瘤可能会导致 FH 的漏诊。